Vaccination Does Not Impact Long COVID Neurological Symptoms
Minor differences in neurologic symptoms seen between prevaccination infection and breakthrough infection
2015 to 2022 Saw Rise in Ketamine Use
Association with depression attenuated in later years, while new sociodemographic risk factors emerged
Differences Exist in Precision Oncology Drug Eligibility Among Patient Ancestral Groups
Patients of African ancestry had the lowest precision oncology drug-based clinical actionability from 2019 onward
Semaglutide Doubles Risk for Nonarteritic Anterior Ischemic Optic Neuropathy
Findings seen for patients with type 2 diabetes during a five-year period
Interviews ID Factors Tied to COVID-19 Vaccine Hesitancy in Black Women
Mistrust in health care and government, concerns over vaccine safety and long-term effects among top factors
MEK Inhibition Beneficial for Children With Subset of Severe Hypertrophic Cardiomyopathy
Decrease in mortality, morbidity seen with trametinib for children with RASopathy-associated hypertrophic cardiomyopathy
Shorter Treatment Regimens Recommended for Tuberculosis
Four-month regimen recommended for drug-susceptible TB and six-month regimen recommended for drug-resistant TB
Polypill Treatment Offers High Value in Low-Income, Underserved Population
Polypill treatment estimated at $8,560 per QALY gained compared with usual care and had high value in 99 percent of simulations
FDA Adds Warning Label to RSV Vaccines Abrysvo and Arexvy
Postmarketing observation shows increased risk for Guillain-Barré syndrome for 42 days postvaccination
Perioperative GLP-1 RA Use Reduces Risk for Complications in Patients With Diabetes
Reduction seen in risk for readmission, wound dehiscence, and hematoma, but no significant differences seen in rates of infection, bleeding
